Search Results

November 2021 "Cambridge’s Japanese-owned life sciences company Sosei Heptares has clinched a lucrative

Among those hitching their wagons to that star are Verily and Sosei Heptares, which have struck a research The financial details of the strategic collaboration weren’t released, but Sosei Heptares’ past two team-ups

December 2021 "Tokyo, Japan and Cambridge, UK, 24 December 2021 – Sosei Group Corporation (“Sosei Heptares under the HSR Act, under the terms of the License Agreement Neurocrine Biosciences has agreed to pay Sosei Heptares an upfront payment of US$100 million, with the amount to be recognized as revenue in the fourth

August 2022 "August 10, 2022 Cancer Research UK is working with global biopharma Sosei Heptares on a

"We recently hosted our annual Scientific Advisory Board (SAB) summit at our site within Granta Park. It was great to bring everyone together and also welcome new member John Parkinson." Read more at the source #DrGPCR #GPCR #IndustryNews

May 2022 Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery "Collaboration is part of Sosei Heptares’ Target Identification and pioneers in drug discovery involving the gut-brain axis, will gain unique and valuable access to the Sosei Heptares compound library for its industry-leading biology platform to identify potential GPCR targets of new gastrointestinal therapeutics Tokyo, Japan, Cambridge, UK and New York, USA – May 17, 2022 – Sosei

July 2022 Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate cancers in combination with other immunotherapies Tokyo, Japan, London and Cambridge, UK, 22 July 2022 – Sosei world’s largest private funder of cancer research, today announce the signing of an agreement to bring Sosei Heptares’ cancer immunotherapy drug candidate into a first-in-human trial."

April 2022 Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage Matt Barnes appointed President of Heptares Therapeutics Ltd., and Head of UK R&D Tokyo, Japan and Cambridge , UK, 24 March 2022 – Sosei Group Corporation (“the Company”; TSE: 4565) today confirms that a series

December 2022 Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and combine Twist’s proprietary synthetic antibody libraries and sophisticated bioinformatics expertise with Sosei Heptares’ world-leading StaR® (stabilized receptor) platform to generate novel antibody leads to disease-relevant GPCR targets Tokyo, Japan and Cambridge, UK, 16 December 2021 – Sosei Group Corporation (“the Company Heptares."

February 2022 Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 "By Cliona MacSweeney | Apr 20, 2022 Cliona MacSweeney, a project director in our Translational Medicine department, recently presented this important pre-clinical work at SIRS2022 confirming the ability of the highly selective novel GPR52 agonist HTL00411718 to modulate centrally mediated locomotor activity in response to A2A receptor antagonists. This work highlights an important interplay between the adenosinergic and dopaminergic systems and suggests the potential for GPR52 agonists to control neuropsychiatric symptoms in conditions such as schizophrenia. " Read more at the source #DrGPCR #GPCR #IndustryNews

Sophie Bradley | Apr 12, 2022 Summary Sophie Bradley, Translational Sciences Associate Director at Sosei Heptares, recently presented at the Keystone Symposia GPCR Conference, a summary of work performed both at Sosei Heptares and Glasgow University characterizing the role of the muscarinic M1 receptor in cognitive

H8 is essential for rhodopsin trafficking to vertebrate photoreceptor outer segments Industry News Sosei Heptares Will Receive US$3.75 Million Payment in Multi-Target Partnership Sosei Heptares Announces Submission Heptares’ Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial Andrew ligand binding with Free Energy Perturbation GPCR Events, Meetings, and Webinars November 10, 2023 | Sosei Heptares Zoom Webinar November 15 - 17, 2023 | MPGPCR Conference November 20 - 23, 2023 | ASCEPT Annual

Septerna Announces the Formation of a Cross-Functional Scientific and Drug Discovery Advisory Board Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases Sosei Heptares Enters R&D Agreements with the University of Oxford and KU Leuven to Identify Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical

Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100 Sosei Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development Progress Parker Meetings, and Webinars November 2 - 4, 2023 | GPCR Retreat- Registration Closed November 10, 2023 | Sosei Heptares Zoom Webinar November 15 - 17, 2023 | MPGPCR Conference November 20 - 23, 2023 | ASCEPT Annual

variants and uncovering the natural mutations of L->Q, I->T, F->Y and Q->L, T->I and Y->F Industry News Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel ) Domain Therapeutics and Chime Biologics Form Manufacturing Pact for Antibody Cancer Immunotherapy Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist

through phylogenetic networks and whole-genome SNP-based analysis Industry News Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals Are GLP-1s finding

Discuss Allosteric Modulators in Neurological Disorders at Jefferies Healthcare Conference in London Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine

InterAx Biotech to Apply its Leading AI and Cell Signalling Technology to Support Target Validation for a Sosei Heptares GPCR Discovery Program Salipro Biotech and DyNAbind Announce Milestone Achievement in Collaboration British Patient Capital Invests £10m in next-generation drug development company OMass Therapeutics Sosei Heptares 2022 ESG report Exscientia Announces Sixth Molecule Created Through Generative AI Platform

Industry News Sosei Heptares and Neurocrine Biosciences won Out-Licensing Deal of the Year from Locust Walk Omass Therapeutics 2022 Review Sosei hooks millions from Eli Lilly alliance Septerna was selected as one of the Top Life Sciences Startups to Watch in 2023 by BioSpace Sosei Heptares Notes its Partner

strengthens Scientific Advisory Board with appointment of immuno-oncology experts More millions roll in for Sosei Heptares Call for GPCR Papers GPCRs: Signal Transduction.

Celebrating Lefkowitz’s 50 Years at Duke Novo Nordisk stops Ozempic kidney trial after early signs of success Sosei and PharmEnable extend neurological disease drugs hunt Sosei Heptares’ President & CEO Chris Cargill

Methyl Relaxation Structural determinants of sphingosine-1-phosphate receptor selectivity Industry News Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Development DKK

shortlisted for ‘Life Sciences and Health Tech Company of the Year’ in the 2023 Thames Valley Tech Awards Sosei Heptares Webinar Presentation for Q2 FY2023 Financial Results Neurocrine Biosciences Announces Appointment

News Addex Reports 2023 Half Year And Second Quarter Financial Results And Provides Corporate Update Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with

Orion Biotechnology attended the Swiss Biotech Day Addex Therapeutics attended the Swiss Biotech Day Sosei Heptares presented novel Computational Chemistry and Cheminformatics approaches for GPCR SBDD at UK

Neurological Disorders Aelis Farma Reports Its 2023 Annual Financial Resultsand Confirms Its 2024 Outlook Sosei Heptares officially changed their name to Nxera Domain Therapeutics to participate at premier investor

Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeutics Sosei Heptares Webinar Presentation for FY2022 Financial Results Call for GPCR Papers GPCRs: Signal Transduction

Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating

Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies Sosei Heptares’ President & CEO Chris Cargill Wins Executive of the Year at the Citeline Pharma Intelligence